249 related articles for article (PubMed ID: 35800882)
1. Comparison of Healthcare Encounters and Drug Persistence in Patients With Pulmonary Arterial Hypertension Receiving Oral Selexipag, Inhaled Iloprost, or Parenteral Treprostinil: A Retrospective Database Analysis.
Song C; Kunovszki P; Beaudet A
J Health Econ Outcomes Res; 2022; 9(1):151-160. PubMed ID: 35800882
[No Abstract] [Full Text] [Related]
2. Comparative evaluation of costs and healthcare resource utilization of oral selexipag versus inhaled treprostinil or oral treprostinil in patients with pulmonary arterial hypertension.
Papademetriou E; Liu X; Beaudet A; Tsang Y; Potluri R; Panjabi S
J Med Econ; 2023; 26(1):644-655. PubMed ID: 37086091
[TBL] [Abstract][Full Text] [Related]
3. Inhaled treprostinil vs iloprost: Comparison of adherence, persistence, and health care resource utilization in patients with pulmonary arterial hypertension.
Burger CD; Wu B; Classi P; Morland K
J Manag Care Spec Pharm; 2023 Jan; 29(1):101-108. PubMed ID: 36580122
[No Abstract] [Full Text] [Related]
4. Comparative effectiveness of oral prostacyclin pathway drugs on hospitalization in patients with pulmonary hypertension in the United States: a retrospective database analysis.
McConnell JW; Tsang Y; Pruett J; Iii WD
Pulm Circ; 2020; 10(4):2045894020911831. PubMed ID: 33240480
[TBL] [Abstract][Full Text] [Related]
5. Medication Adherence and Healthcare Costs Among Patients with Pulmonary Arterial Hypertension Treated with Oral Prostacyclins: A Retrospective Cohort Study.
Dean BB; Saundankar V; Stafkey-Mailey D; Anguiano RH; Nelsen AC; Gordon K; Classi P
Drugs Real World Outcomes; 2020 Sep; 7(3):229-239. PubMed ID: 32144746
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of transitioning from selexipag to oral treprostinil in pulmonary arterial hypertension: Findings from the ADAPT registry.
Lachant D; Minkin R; Swisher J; Mogri M; Zolty R; Hwang S; Seaman S; Broderick M; Sahay S
Pulm Pharmacol Ther; 2023 Oct; 82():102232. PubMed ID: 37451609
[TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study.
Frost A; Janmohamed M; Fritz JS; McConnell JW; Poch D; Fortin TA; Miller CE; Chin KM; Fisher M; Eggert M; McEvoy C; Benza RL; Farber HW; Kim NH; Pfister T; Shiraga Y; McLaughlin V
J Heart Lung Transplant; 2019 Jan; 38(1):43-50. PubMed ID: 30391194
[TBL] [Abstract][Full Text] [Related]
8. Rapid transition from oral selexipag to parenteral treprostinil in a patient with mixed-etiology pulmonary hypertension.
Radosevich JJ; DeChristopher A; Irandost M; Fann J; Feldman J
Am J Health Syst Pharm; 2020 Jul; 77(15):1208-1212. PubMed ID: 32620953
[TBL] [Abstract][Full Text] [Related]
9. A Case Report of a Patient With Pulmonary Arterial Hypertension Transitioned From Inhaled Iloprost to Selexipag.
Verlinden NJ; Walter C; Raina A; Benza RL
J Pharm Pract; 2021 Dec; 34(6):980-983. PubMed ID: 32912036
[TBL] [Abstract][Full Text] [Related]
10. Assessment of Inhaled Treprostinil Palmitil, Inhaled and Intravenous Treprostinil, and Oral Selexipag in a Sugen/Hypoxia Rat Model of Pulmonary Arterial Hypertension.
Corboz MR; Plaunt AJ; Malinin VS; Li Z; Gauani H; Chun D; Cipolla D; Perkins WR; Chapman RW
J Pharmacol Exp Ther; 2022 Oct; 383(1):103-116. PubMed ID: 36507843
[TBL] [Abstract][Full Text] [Related]
11. Safe and successful transition from oral selexipag to subcutaneous treprostinil in a patient with idiopathic pulmonary arterial hypertension treated with triple combination therapy.
Adachi S; Nishiyama I; Yasuda K; Yoshida M; Nakano Y; Kondo T; Murohara T
J Cardiol Cases; 2022 Jul; 26(1):42-45. PubMed ID: 35923524
[TBL] [Abstract][Full Text] [Related]
12. Different efficacy of inhaled and oral medications in pulmonary hypertension.
AbuHalimeh BJ; Parambil JG; Tonelli AR
Heart Lung; 2017; 46(4):334-337. PubMed ID: 28527831
[TBL] [Abstract][Full Text] [Related]
13. Rapid transition from inhaled iloprost to inhaled treprostinil in patients with pulmonary arterial hypertension.
Bourge RC; Tapson VF; Safdar Z; Benza RL; Channick RN; Rosenzweig EB; Shapiro S; White RJ; McSwain CS; Gotzkowsky SK; Nelsen AC; Rubin LJ
Cardiovasc Ther; 2013 Feb; 31(1):38-44. PubMed ID: 22970909
[TBL] [Abstract][Full Text] [Related]
14. Oral Prostacyclin Pathway Agents Used in PAH: A Targeted Literature Review.
Burger CD; Tsang Y; Chivers M; Vekaria RV; Doad G; Atkins N; Panjabi S
Clinicoecon Outcomes Res; 2024; 16():447-459. PubMed ID: 38831921
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness of prostacyclins in pulmonary arterial hypertension.
Roman A; Barberà JA; Escribano P; Sala ML; Febrer L; Oyagüez I; Sabater E; Casado MA
Appl Health Econ Health Policy; 2012 May; 10(3):175-88. PubMed ID: 22452448
[TBL] [Abstract][Full Text] [Related]
16. Impact of selexipag use within 12 months of pulmonary arterial hypertension diagnosis on hospitalizations and medical costs: A retrospective cohort study.
Tsang Y; Stokes M; Kim YJ; Tilney R; Panjabi S
Clin Respir J; 2023 Dec; 17(12):1209-1222. PubMed ID: 37804160
[TBL] [Abstract][Full Text] [Related]
17. Hospitalization Among Pulmonary Arterial Hypertension Patients With and Without Connective Tissue Disease Comorbidities Prescribed Oral Selexipag.
Tsang Y; Singh R; Verma S; Panjabi S
Rheumatol Ther; 2023 Jun; 10(3):741-756. PubMed ID: 36959524
[TBL] [Abstract][Full Text] [Related]
18. A multicenter, retrospective study of patients with pulmonary arterial hypertension transitioned from parenteral prostacyclin therapy to inhaled iloprost.
Channick RN; Frantz RP; Kawut SM; Palevsky H; Tumuluri R; Sulica R; Lauto PO; Benton WW; de Boisblanc B
Pulm Circ; 2013 Apr; 3(2):381-8. PubMed ID: 24015339
[TBL] [Abstract][Full Text] [Related]
19. Transition from treprostinil to selexipag in patients with pulmonary arterial hypertension: Case series.
Fanous SM; Janmohamed M
Am J Health Syst Pharm; 2018 Dec; 75(23):1877-1881. PubMed ID: 30301721
[TBL] [Abstract][Full Text] [Related]
20. Prostacyclin for pulmonary arterial hypertension.
Barnes H; Yeoh HL; Fothergill T; Burns A; Humbert M; Williams T
Cochrane Database Syst Rev; 2019 May; 5(5):CD012785. PubMed ID: 31042010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
